Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 22 (14), 4869-72

Identification of a Dual δ OR Antagonist/μ OR Agonist as a Potential Therapeutic for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Affiliations

Identification of a Dual δ OR Antagonist/μ OR Agonist as a Potential Therapeutic for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Henry J Breslin et al. Bioorg Med Chem Lett.

Abstract

A small set of acyclic analogs 5 were prepared to explore their structure-activity relationships (SARs) relative to heterocyclic core, opioid receptor (OR) agonists 4. Compound 5l was found to have very favorable OR binding affinities at the δ and μ ORs (r K(i) δ=1.3 nM; r K(i) μ=0.9 nM; h K(i) μ=1.7 nM), with less affinity for the κ OR (gp K(i) κ=55 nM). The OR functional profile for 5l varied from the previously described dual δ/μ OR agonists 4, with 5l being a potent, mixed dual δ OR antagonist/μ OR agonist [δ IC(50)=89 nM (HVD); μ EC(50)=1 nM (GPI); κ EC(50)=1.6 μM (GPC)]. Compound 5l has progressed through a clinical Phase II Proof of Concept study on 800 patients suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-d). This Phase II study was recently completed successfully, with 5l demonstrating statistically significant efficacy over placebo.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

MeSH terms

Substances

LinkOut - more resources

Feedback